F S&P 500
5,157.75 +3.00 (+0.06%) F Dow Jones
38,865.00 +33.00 (+0.08%) F Nasdaq
17,993.75 -7.00 (-0.04%) E-mini Russell 2000 Index Futur
2,052.40 +6.60 (+0.32%) Petróleo
78.47 +0.36 (+0.46%) Oro
2,320.10 +11.50 (+0.50%)
Apellis Pharmaceuticals, Inc. (APLS)
Fuera de horario:
Apellis Pharmaceuticals, Inc.
100 Fifth Avenue
Waltham, MA 02451
United States
617 977 5700
https://www.apellis.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 702
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Cedric Francois M.D., Ph.D. | Co-Founder, President, CEO & Director | 1.44M | 35.28M | 1972 |
| Mr. Alec Machiels J.D., MBA | Co-Founder & Director | 90.62k | N/D | 1973 |
| Mr. Timothy E. Sullivan | CFO & Treasurer | 793.43k | 6.67M | 1971 |
| Mr. Adam J. Townsend | Chief Operating Officer | 770.44k | 6.29M | 1978 |
| Mr. David O. Watson Esq., J.D. | General Counsel | 764.37k | 344.47k | 1973 |
| Dr. Caroline R. Baumal M.D. | Chief Medical Officer | 1.01M | N/D | 1968 |
| Dr. Pascal Deschatelets Ph.D. | Co-Founder & Chief Scientific Officer | 688.05k | 8.37M | 1970 |
| Mr. James G. Chopas CPA | VP, Corporate Controller & Chief Accounting Officer | N/D | N/D | 1967 |
| Ms. Meredith Kaya | Senior Vice President, Investor Relations & Strategic Finance | N/D | N/D | N/D |
| Ms. Karen Lewis | Chief People Officer | N/D | N/D | 1973 |
Descripción
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
Gestión corporativa
La calificación ISS Governance QuickScore de Apellis Pharmaceuticals, Inc. a partir del 1 de mayo de 2024 es 6. Las puntuaciones principales son Auditoría: 4; Junta: 6; Derechos del accionista: 8; Compensación: 4.
